ACHIEVEMENT OF LOW DISEASE ACTIVITY IN PATIENTS INITIATING INFLIXIMAB WITH AND WITHOUT DOSE ESCALATION

被引：0

作者：

Cohen, S. ^{[1
]}

Reed, G. ^{[2
]}

Magner, R. ^{[3
]}

Kafka, S. ^{[4
]}

Ellis, L. ^{[4
]}

DeHoratius, R. J. ^{[5
]}

Greenberg, J. D. ^{[6
]}

机构：

[1] Metroplex Clin Res Ctr, Dallas, TX USA

[2] LLC Mass Med Sch, Corrona, Southborough, MA USA

[3] U Mass Med Sch, Worcester, MA USA

[4] Janssen Sci Affairs LLC, Horsham, PA USA

[5] Horsham Phila, LLC Kimmel Sch Med, Janssen Sci Affairs, Horsham, PA USA

[6] NYU, LLC, Sch Med, Corrona, Southborough, NY USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷

关键词：

D O I：

10.1136/annrheumdis-2016-eular.2771

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

THU0156

引用

页码：238 / 239

页数：2

共 50 条

[11] SIBDQ Score Does Not Predict the Need for Dose Escalation of Infliximab in Inflammatory Bowel Disease Patients [J].

Parian, Alyssa M. ;

Thul, Bonny ;

Dudley-Brown, Sharon ;

Lazarev, Mark .

GASTROENTEROLOGY, 2012, 142 (05) :S660-S660

[12] Time of infliximab therapy initiation and dose escalation in Crohn's disease [J].

Mindy CW Lam ;

Terry Lee ;

Kenneth Atkinson ;

Brian Bressler .

World Journal of Gastroenterology, 2014, (01) :214-218

[13] Time of infliximab therapy initiation and dose escalation in Crohn's disease [J].

Lam, Mindy C. W. ;

Lee, Terry ;

Atkinson, Kenneth ;

Bressler, Brian .

WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (01) :214-218

[14] Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial [J].

Hisamatsu, Tadakazu ;

Kunisaki, Reiko ;

Nakamura, Shiro ;

Tsujikawa, Tomoyuki ;

Hirai, Fumihito ;

Nakase, Hiroshi ;

Watanabe, Kenji ;

Yokoyama, Kaoru ;

Nagahori, Masakazu ;

Kanai, Takanori ;

Naganuma, Makoto ;

Michimae, Hirofumi ;

Andoh, Akira ;

Yamada, Akihiro ;

Yokoyama, Tadashi ;

Kamata, Noriko ;

Tanaka, Shinji ;

Suzuki, Yasuo ;

Hibi, Toshifumi ;

Watanabe, Mamoru .

INTESTINAL RESEARCH, 2018, 16 (03) :494-+

[15] No effect of dose escalation of infliximab in patients with rheumatoid arthritis with residual activity - Data from national registry [J].

Pavelka, K. ;

Tegzova, D. ;

Pavelkova, A. ;

Vencovsky, J. ;

Jarosova, K. ;

Forejtova, S. ;

Chroust, K. .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 :56-56

[16] Infliximab dose escalation in patients with rheumatoid arthritis in the START study: Influence of Infliximab pharmacokinetics and immunogenicity [J].

Rahman, M. U. ;

Strusberg, I. ;

Geusens, P. ;

Wagner, C. ;

Han, J. ;

Westhovens, R. .

ZEITSCHRIFT FUR RHEUMATOLOGIE, 2007, 66 :86-86

[17] Infliximab dose escalation in patients with rheumatoid arthritis in the start trial: The effect of infliximab pharmacokinetics and immunogenicity [J].

Rahman, M. U. ;

Strusberg, I. ;

Geusens, P. ;

Berman, A. ;

Wagner, C. ;

Fasanmade, A. ;

Han, J. ;

Westhovens, R. .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 :184-185

[18] Comparison of Dose Escalation and Co-Therapy Intensification Between Patients with Rheumatoid Arthritis Initiating Biologic Treatment with Etanercept, Adalimumab and Infliximab [J].

Thorne, J. Carter ;

Boire, Gilles ;

Chow, Andrew ;

Garces, Kirsten ;

Liu, Fang ;

Poulin-Costello, Melanie ;

Walker, Valery ;

Haraoui, Boulos .

ARTHRITIS & RHEUMATOLOGY, 2015, 67

[19] Comparison of Dose Escalation and Co-therapy Intensification between Patients with Rheumatoid Arthritis Initiating Biologic Treatment with Etanercept, Adalimumab and Infliximab [J].

Thorne, Carter ;

Boire, Gilles ;

Chow, Andrew ;

Garces, Kirsten ;

Poulin-Costello, Melanie ;

Walker, Valery ;

Haraoui, Boulos .

JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) :1171-1171

[20] Infliximab dose escalation in RA patients: PK & immunogenicity in the start trial [J].

Westhovens, R. ;

Rahman, M. U. ;

Strusberg, I. ;

Geusens, P. ;

Berman, A. ;

Wagner, C. ;

Fasanmade, A. ;

Xu, S. ;

Han, J. .

RHEUMATOLOGY, 2008, 47 :II15-II15

← 1 2 3 4 5 →